Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
54 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Amicus Therapeutics, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Amicus Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Amicus Therapeutics, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Amicus Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Amicus Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Amicus Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Amicus Therapeutics, Inc.'s pipeline products Reasons to buy - Evaluate Amicus Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Amicus Therapeutics, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Amicus Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Amicus Therapeutics, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Amicus Therapeutics, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Amicus Therapeutics, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Amicus Therapeutics, Inc. Snapshot 5 Amicus Therapeutics, Inc. Overview 5 Key Information 5 Key Facts 5 Amicus Therapeutics, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Amicus Therapeutics, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Combination Treatment Modalities 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 Amicus Therapeutics, Inc. - Pipeline Products Glance 14 Amicus Therapeutics, Inc. - Late Stage Pipeline Products 14 Phase III Products/Combination Treatment Modalities 14 Amicus Therapeutics, Inc. - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Phase I Products/Combination Treatment Modalities 16 Amicus Therapeutics, Inc. - Early Stage Pipeline Products 17 Preclinical Products/Combination Treatment Modalities 17 Discovery Products/Combination Treatment Modalities 18 Amicus Therapeutics, Inc. - Drug Profiles 19 migalastat hydrochloride 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 afegostat tartrate 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 duvoglustat hydrochloride + alglucosidase alfa 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 migalastat hydrochloride + Enzyme Replacement Therapy 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 (migalastat hydrochloride + agalsidase alfa) 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 AT-3375 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 ATB-200 + Chaperone 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Chaperone-ERT Combinations 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 laronidase + Chaperone 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Recombinant Enzyme For Lysosomal Storage Disorder 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Recombinant Enzyme For Gaucher Disease 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Amicus Therapeutics, Inc. - Pipeline Analysis 33 Amicus Therapeutics, Inc. - Pipeline Products by Target 33 Amicus Therapeutics, Inc. - Pipeline Products by Route of Administration 34 Amicus Therapeutics, Inc. - Pipeline Products by Molecule Type 35 Amicus Therapeutics, Inc. - Pipeline Products by Mechanism of Action 36 Amicus Therapeutics, Inc. - Recent Pipeline Updates 37 Amicus Therapeutics, Inc. - Dormant Projects 44 Amicus Therapeutics, Inc. - Company Statement 45 Amicus Therapeutics, Inc. - Locations And Subsidiaries 52 Head Office 52 Other Locations & Subsidiaries 52 Appendix 53 Methodology 53 Coverage 53 Secondary Research 53 Primary Research 53 Expert Panel Validation 53 Contact Us 54 Disclaimer 54
List of Tables Amicus Therapeutics, Inc., Key Information 5 Amicus Therapeutics, Inc., Key Facts 5 Amicus Therapeutics, Inc. - Pipeline by Indication, 2014 8 Amicus Therapeutics, Inc. - Pipeline by Stage of Development, 2014 9 Amicus Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 10 Amicus Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2014 11 Amicus Therapeutics, Inc. - Partnered Products in Pipeline, 2014 12 Amicus Therapeutics, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 13 Amicus Therapeutics, Inc. - Phase III, 2014 14 Amicus Therapeutics, Inc. - Phase II, 2014 15 Amicus Therapeutics, Inc. - Phase I, 2014 16 Amicus Therapeutics, Inc. - Preclinical, 2014 17 Amicus Therapeutics, Inc. - Discovery, 2014 18 Amicus Therapeutics, Inc. - Pipeline by Target, 2014 33 Amicus Therapeutics, Inc. - Pipeline by Route of Administration, 2014 34 Amicus Therapeutics, Inc. - Pipeline by Molecule Type, 2014 35 Amicus Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 36 Amicus Therapeutics, Inc. - Recent Pipeline Updates, 2014 37 Amicus Therapeutics, Inc. - Dormant Developmental Projects,2014 44 Amicus Therapeutics, Inc., Subsidiaries 52
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
